Table 3 Univariate analysis of prognostic factors in patients (n = 69) with neuroblastoma
Variables | Case number | 5-year event-free survival, % (SE) | P value | 5-year overall survival, % (SE) | P value |
|---|---|---|---|---|---|
Age at diagnosis (months) | 0.001* | 0.001* | |||
≦18 months | 32 | 75.8 (8) | 81.4 (7.7) | ||
>18 months | 37 | 20.1 (7.5) | 21.1 (9.6) | ||
International Neuroblastoma Staging System stage | <0.001* | <0.001* | |||
1, 2, 4s | 23 | 90.2 (6.6) | 95.2 (4.6) | ||
3, 4 | 46 | 22 (7.1) | 38.2 (8.5) | ||
Primary tumor site | 0.57 | 0.412 | |||
Adrenal | 53 | 45.3 (7.4) | 52.3 (8) | ||
Extraadrenal | 16 | 46.7 (15.1) | 76 (12.3) | ||
International Neuroblastoma Pathology Classification histology | <0.001* | <0.001* | |||
Favorable | 33 | 77.1 (8.3) | 86.5 (7.4) | ||
Unfavorable | 36 | 19.9 (7.2) | 33 (9) | ||
MYCN | 0.034* | 0.03* | |||
Amplified | 17 | 22.1 (13) | 38.1 (15) | ||
Non-amplified | 52 | 52.1 (7.6) | 62.5 (7.9) | ||
Children’s Oncology Group risk group | <0.001* | <0.001* | |||
Nonhigh risk | 25 | 90.4 (6.5) | 93.3 (6.4) | ||
High risk | 44 | 21.8 (7) | 38.9 (8.5) | ||
MYCN RNA in situ hybridization expression | <0.001* | <0.001* | |||
Low | 39 | 76.3 (7.9) | 79.1 (8.6) | ||
High | 30 | 9.2 (6) | 16.1 (8.2) |
